The manufacturing records for the onxmc-25/33 sn (b)(6) were reviewed, and it was confirmed that all records were controlled, available for review, and met all specifications per the device master record.All lots passed functional testing and met release specifications.During the investigation no non-conformances or deviations were noted.Document change orders le 14228, le 14669, were issued for leaflet tuning as a part of the standard manufacturing process.A review of the available information was performed.According to the report, "we had a young lady who stopped taking warfarin, who came in with a thrombosed onyx mitral valve.The serial number of the valve was (b)(6).It was a 25/33 valve.We proceeded to take it out and put a tissue valve and she is doing fine." we do not have any objective medical records to corroborate the assessment.We do not have a date of surgery, so we do not know the elapsed time until the thrombosis was diagnosed.The information provided suggests an aortic on-x valve thrombosed following inadequate anticoagulation therapy.Thrombosis is a rare but known potential complication of prosthetic valve replacement [ifu] occurring at a historical rate of 0.8% per patient-year for rigid heart valves.The ifu states the recommended anticoagulation therapy and acknowledges the possibility of complications such as thrombosis with the potential for reoperation and explantation.This is a case of valve thrombosis, but we do not know the origin nor age of the clot.The information provided points to inadequate anticoagulation as the likely cause.However, a definitive root cause remains unknown.No further action is required without additional information.This report is being submitted as required by federal regulations and does not constitute an admission that the device caused or contributed to the reported event.Furthermore, this report reflects the event as alleged by the complainant and does not imply that the information reported to cryolife is accurate or has been confirmed by cryolife.
|